The results of two long-awaited clinical trials are expected to be the focal point of discussion during the annual American College of Cardiology meeting that will be held in March in San Francisco. One of those trials is the PREVAIL trial, which is testing Boston Scientific’s Watchman left atrial appendage closure device that is used to prevent strokes in AF patients.

The Watchman device is an implant that “closes the left atrial appendage, the source of the great majority of strokes in patients with atrial fibrillation.” There has been a great deal of interest in this trial ever since the PROTECT AF trial took place in 2009. However, the FDA has been concerned about the device regardless of it getting a good recommendation from the Circulatory Systems Devices panel, which is necessary before an important clinical trial can be conducted. The PREVAIL trial is to compare the effects of Warfarin for stroke prevention against the safety and efficacy of the Watchman device.

Atrial fibrillation (AF) is a condition that is caused by patients suffering from irregular heartbeats and flutters. Doctors have been searching for a treatment for AF that can safely prevent strokes and lessen the recurrence of the condition. So far they use catheter ablations and prescription drugs most commonly, but the medications have proven very dangerous. One such medication that can often have potentially fatal consequences is Multaq. Multaq has been linked to serious conditions which include liver failure and a worsening of the heart condition. Most recently, the drug has been linked to lung disease and pulmonary toxicity as well.

If you or a family member has been diagnosed with liver failure, lung disease, pulmonary toxicity or a worsening of your heart condition after taking Multaq, contact attorney Greg Jones for a free consultation today. I am experienced at fighting Multaq lawsuits and may be able to get you money for your injuries.